Abbvie Inc

NYSE: ABBV
$159.62
-$7.67 (-4.6%)
Closing price April 26, 2024
Abbvie Inc. is a global pharmaceutical company that focuses on discovering, developing, manufacturing, and selling a wide range of treatments. Its portfolio includes therapies for autoimmune diseases, various cancers, eye diseases, neurological disorders, and more. Notable products include Humira for autoimmune conditions, Skyrizi and Rinvoq for skin and joint diseases, and Imbruvica for blood cancers. AbbVie also offers products in aesthetics, women's health, and eye care. Founded in 2012 and based in North Chicago, Illinois, AbbVie collaborates with several biotech firms to advance its research in oncology and immunology.
Given the looming potential for massive downside as interest rates head higher, these seven Dividend Aristocrat stocks in defensive sectors that look poised to do well for the rest of 2022 and into...
The bear market rally that started in June is over and it is clearly a time to move to safer dividend stocks. These eight outstanding health care stocks make sense for worried investors now as they...
Monday's additional top analyst upgrades and downgrades included AbbVie, American Eagle, Bumble, Palo Alto Networks, SiriusXM, Stanley Black & Decker, Target and more.
The two largest U.S. oil & gas companies report earnings before markets open Friday along with a pharmaceutical and a consumer staples giant.
These seven top companies have some of the highest payouts in the Dividend Aristocrat universe. They supply products or services unlikely to go out of style or demand, and their stocks are rated Buy...
Investors seeking dividend dependability may be drawn to the Dividend Kings, those companies that have raised their dividends for at least 50 consecutive years. These are the seven highest-yielding...
With the potential for massive downside still looming and interest rates definitely going higher, 24/7 Wall St. searched for Dividend Aristocrat stocks that are in sectors that are defensive but that...
Investors worried about rising rates and stock volatility may want to consider these seven Dividend King stocks that should still do well even if the Federal Reserve delivers a 75-basis-point...
The founder of Tesla and SpaceX says he has a "super bad feeling" about the economy. These nine Dividend Aristocrats are in sectors that are defensive and they look poised to do well for the next six...
Monday's additional analyst calls were on AbbVie, Array Technologies, Dow, DTE Energy, Gap, Pfizer, Ralph Lauren, Trimble and more.
With the market seemingly poised to head much lower, it may be time for investors to move any capital invested in momentum or high beta stocks to one or more of the safest Dividend Kings. Here are...
Friday's top analyst upgrades and downgrades included AbbVie, Amazon.com, APA, CF Industries, Costco Wholesale, eBay, Etsy, GoDaddy, Intercontinental Exchange, Lululemon Athletica, Match, MetLife,...
With the potential for a sizable correction looming, 24/7 Wall St. thought it would be a good idea to look for Dividend Aristocrats that are in defensive sectors but look poised to do well the rest...
Any company that has paid rising dividends for 50 years or more is the epitome of safe and dependable. These seven outstanding stocks also have support from top Wall Street analysts, making them...
Here are previews of three pharmaceutical giants set to report earnings before markets open on Friday.